Spoken Alpha
RELMADA THERAPEUTICS, INC.
Relmada Therapeutics develops novel drug candidates for cancer and neurological disorders. The company's lead program, NDV-01, is a controlled-release bladder cancer treatment currently in Phase 2 trials, with Phase 3 studies planned for mid-2026.
RELMADA THERAPEUTICS, INC is a Healthcare company operating in Biotechnology with a $482.1M market cap.
RLMD beat consensus EPS by 0.5% in Q2 FY2026, reported Aug 5, 2026.
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for RLMD.
$ curl https://api.spokenalpha.com/v1/companies/RLMDFAQ
Spoken Alpha indexes RLMD's earnings call transcripts at https://spokenalpha.com/companies/RLMD. Each call links to attributed speakers and parsed analyst Q&A.
RELMADA THERAPEUTICS, INC. (RLMD) held its most recent earnings call on 2026-08-06, covering fiscal Q2 2026.
RELMADA THERAPEUTICS, INC. (RLMD) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-05 | $-0.11 | $-0.21 | +47.6% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-12 | $-0.22 | $-0.20 | -12.8% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $-0.29 | $-0.14 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.30 | $-0.04 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-06 | $-0.30 | $-0.25 | -20.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.58 | $-0.31 | -87.1% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-16 | $-0.62 | $-0.70 | +11.4% | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.72 | $-0.64 | -12.5% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-06 | $-0.59 | $-0.83 | +28.9% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-07 | $-0.72 | $-0.86 | +16.3% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-18 | $-0.84 | $-0.83 | -1.2% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-07 | $-0.73 | $-0.91 | +19.8% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.84 | $-0.90 | +6.7% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.87 | $-0.89 | +2.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-22 | $-1.41 | $-1.33 | -6.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-1.26 | $-1.47 | +14.3% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-1.08 | $-1.32 | +18.2% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-04 | $-1.40 | $-1.22 | -14.8% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-22 | $-1.80 | $-1.83 | +1.6% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-10 | $-2.42 | $-1.55 | -56.1% | $0 | — | — | EODHD |
Source: EODHD. RLMD reported actuals as published; sparse fields render as —.